Dopamine Agents (poisoning) < Dopamine Agents (therapeutic use) < Dopamine Agents (toxicity)

Facettes :

List of bibliographic references

Number of relevant bibliographic references: 77.
[0-20] [0 - 20][0 - 50][20-40]

Ident.	Authors (with country if any)	Title
000217 (2000)	C W Olanow [États-Unis] ; A H Schapira ; T. Roth	Waking up to sleep episodes in Parkinson's disease.
000297 (2000)	J. Kulisevsky [Espagne] ; C. García-Sánchez ; M L Berthier ; M. Barbanoj ; B. Pascual-Sedano ; A. Gironell ; A. Estévez-González	Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients.
000364 (2000)	H A Hana Asi [Turquie] ; G. Kaptanoglu ; H A Sahin ; M. Emre	The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa.
000512 (2001)	P. Del Dotto [Italie] ; N. Pavese ; G. Gambaccini ; S. Bernardini ; L V Metman ; T N Chase ; U. Bonuccelli	Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.
000790 (2002)	Oleh Hornykiewicz [Autriche]	Dopamine miracle: from brain homogenate to dopamine replacement.
000886 (2002)	Ronald K B. Pearce [Royaume-Uni] ; Lance A. Smith ; Michael J. Jackson ; Tara Banerji ; Jorgen Scheel-Krüger ; Peter Jenner	The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets.
000B35 (1992)	B. Gomez-Mancilla [Canada] ; R. Boucher ; P J Bédard	Effect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of parkinsonism.
000B38 (1992)	S A Factor [États-Unis] ; D. Brown	Clozapine prevents recurrence of psychosis in Parkinson's disease.
000B91 (2003)	Jau-Shin Lou [États-Unis] ; Greg Kearns ; Theodore Benice ; Barry Oken ; Gary Sexton ; John Nutt	Levodopa improves physical fatigue in Parkinson's disease: a double-blind, placebo-controlled, crossover study.
000D51 (2004)	Nicola Pavese [Royaume-Uni] ; Ornella Rimoldi ; Alexander Gerhard ; David J. Brooks ; Paola Piccini	Cardiovascular effects of methamphetamine in Parkinson's disease patients.
000E42 (2004)	Marcin Zach [Pologne] ; Andrzej Friedman ; Jarosław Sławek ; Mirosława Derejko	Quality of life in Polish patients with long-lasting Parkinson's disease.
000F75 (2004)	Yoshiaki Furukawa [Canada] ; James J. Filiano ; Stephen J. Kish	Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations.
001025 (2004)	Arthur S. Walters [États-Unis] ; William G. Ondo ; Tilman Dreykluft ; Ron Grunstein ; Daniel Lee ; Kapil Sethi	Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study.
001077 (2004)	Reinhard Horowski ; Sven J Hnichen ; Heinz H. Pertz	Fibrotic valvular heart disease is not related to chemical class but to biological function: 5-HT2B receptor activation plays crucial role.
001381 (2005)	Anthony E. Lang [Canada]	Treatment of progressive supranuclear palsy and corticobasal degeneration.
001382 (2005)	David J. Burn [Royaume-Uni] ; Naomi M. Warren	Toward future therapies in progressive supranuclear palsy.
001633 (2006)	Juan Carlos G Mez-Esteban [Espagne] ; Juan Jose Zarranz ; Elena Lezcano ; Fernando Velasco ; Roberto Ciordia ; Idoia Rouco ; Jose Losada ; Iker Bilbao	Sleep complaints and their relation with drug treatment in patients suffering from Parkinson's disease.
001678 (2006)	Anette Schrag [Royaume-Uni] ; Cristina Sampaio ; Nicholas Counsell ; Werner Poewe [Autriche]	Minimal clinically important change on the unified Parkinson's disease rating scale.
001980 (2007)	Anthony P. Nicholas [États-Unis]	Levodopa-induced hyperactivity in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
001A78 (2007)	John M. Ringman	Serendipitous improvement in the Yips associated with memantine use.
001C16 (2007)	Wolfgang H. Oertel [Allemagne] ; Claudia Trenkwalder ; Marco Zucconi ; Heike Benes ; Diego Garcia Borreguero ; Claudio Bassetti ; Markku Partinen ; Luigi Ferini-Strambi ; Karin Stiasny-Kolster	State of the art in restless legs syndrome therapy: practice recommendations for treating restless legs syndrome.

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Curation

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/KwdEn.i -k "Dopamine Agents (therapeutic use)" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/KwdEn.i  \
                -Sk "Dopamine Agents (therapeutic use)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Ncbi
   |étape=   Curation
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Dopamine Agents (therapeutic use)
}}

---

This area was generated with Dilib version V0.6.23. Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024